

Herantis Pharma to participate in Redeye Hosted Events: Investor Lunch and Redeye Growth Day

Herantis Pharma Plc, Press Release, 23 May 2023 at 10:00 A.M. EEST

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that Redeye will be hosting events for investors with Herantis Pharma, CEO Antti Vuolanto, and CFO Tone Kvåle.

Lunch meeting: Following the recent announcement of the first-in-human clinical study start, Herantis will give a company update, followed by discussion/Q&A. As an introduction, Redeye analyst Fredrik Thor will give a brief case summary and his view of the investment case.

Date: Wednesday, May 31, 2023

Time: 12.00-13.00 CEST (lunch will be served)

Location: Redeye AB, Mäster Samuelsgatan 42, 10th floor, Stockholm

Please respond with your interest to participate to thomas.nyberg@redeye.se

Redeye Growth Day will take place June 1, 2023 at the same location.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com